{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:10:30Z","timestamp":1785553830267,"version":"3.56.0"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA155258"],"award-info":[{"award-number":["CA155258"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA155258"],"award-info":[{"award-number":["CA155258"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX001584"],"award-info":[{"award-number":["BX001584"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Transcription factors and their cofactors are major and selective nononcogene dependencies in multiple myeloma cells. By performing a gain-of-function perturbation screen in human multiple myeloma cell lines, we identified the inhibitor of DNA binding (ID) genes as putative suppressors of multiple myeloma cell fitness. Among them, ID2 was found to be downregulated in multiple myeloma patient cells and acted as a tumor suppressor by directly binding and repressing the basic helix-loop-helix factor TCF3, also known as E2A. Lower ID2 expression in multiple myeloma cells conferred a proliferative advantage by increasing TCF3 activity, leading to a dependency on this transcription factor. In contrast, ID2 overexpression reduced TCF3 binding to DNA, which resulted in cell-cycle arrest and a halt in multiple myeloma cell proliferation. The myeloma bone marrow milieu supported this process by further decreasing the expression of ID2 and enhancing TCF3 activity, partly via IL6, revealing a mechanism by which the tumor microenvironment affects multiple myeloma cell behavior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Multiple myeloma cells exploit the oncogenic and proliferative potential of TCF3 by downregulating the transcriptional regulator ID2, a process facilitated by the bone marrow microenvironment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0048","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:32:06Z","timestamp":1760704326000},"page":"129-141","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1432-9742","authenticated-orcid":false,"given":"Mariateresa","family":"Fulciniti","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-6425","authenticated-orcid":false,"given":"Yao","family":"Yao","sequence":"additional","affiliation":[{"name":"2Blood Diseases Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-403X","authenticated-orcid":false,"given":"Tommaso","family":"Perini","sequence":"additional","affiliation":[{"name":"3Laboratory of Age Related Diseases, Division of Genetics and Cell Biology and Hematology and Bone Marrow Transplantation Unit, IRCCS Ospedale San Raffaele, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9464-8804","authenticated-orcid":false,"given":"Jessica","family":"Fong Ng","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-4279","authenticated-orcid":false,"given":"Ana\u00efs","family":"Schavgoulidze","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6564-8552","authenticated-orcid":false,"given":"Shuhui","family":"Deng","sequence":"additional","affiliation":[{"name":"4State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-6782","authenticated-orcid":false,"given":"Jian","family":"Cui","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4479-9822","authenticated-orcid":false,"given":"Jessica","family":"Encinas Mayoral","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2868-739X","authenticated-orcid":false,"given":"Francesco","family":"Ladisa","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-8019","authenticated-orcid":false,"given":"Ryan M.","family":"Young","sequence":"additional","affiliation":[{"name":"5Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-8345","authenticated-orcid":false,"given":"Charles B.","family":"Epstein","sequence":"additional","affiliation":[{"name":"6The Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-4321","authenticated-orcid":false,"given":"Cassandra M.","family":"White","sequence":"additional","affiliation":[{"name":"6The Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-7241","authenticated-orcid":false,"given":"Christopher J.","family":"Ott","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."},{"name":"8Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-0095","authenticated-orcid":false,"given":"Annamaria","family":"Gulla","sequence":"additional","affiliation":[{"name":"9Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4223-2006","authenticated-orcid":false,"given":"Shannon M.","family":"Matulis","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Medical Oncology and the Winship Cancer Institute at Emory University, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"11Division of Hematology, Brigham and Women\u2019s Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-0442","authenticated-orcid":false,"given":"Eugenio","family":"Morelli","sequence":"additional","affiliation":[{"name":"9Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy."},{"name":"12Department of Oncology, University of Torino, Candiolo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Medical Oncology and the Winship Cancer Institute at Emory University, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Mayo Clinic, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6198-3405","authenticated-orcid":false,"given":"Raphael","family":"Szalat","sequence":"additional","affiliation":[{"name":"14Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-5682","authenticated-orcid":false,"given":"Mehmet K.","family":"Samur","sequence":"additional","affiliation":[{"name":"15Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"16VA Boston Healthcare System, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2026011203072886000_bib1","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-20-4366","article-title":"Functional impact of genomic complexity on the transcriptome of multiple myeloma","volume":"27","author":"Ziccheddu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026011203072886000_bib2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41556-021-00766-y","article-title":"Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma","volume":"23","author":"Frede","year":"2021","journal-title":"Nat Cel Biol"},{"key":"2026011203072886000_bib3","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2026011203072886000_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-023-00787-w","article-title":"Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma","volume":"13","author":"Kurata","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026011203072886000_bib5","doi-asserted-by":"crossref","first-page":"12696","DOI":"10.1038\/s41598-022-16940-7","article-title":"Exploiting gene dependency to inform drug development for multiple myeloma","volume":"12","author":"Went","year":"2022","journal-title":"Sci Rep"},{"key":"2026011203072886000_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nri2507","article-title":"E and ID proteins branch out","volume":"9","author":"Kee","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2026011203072886000_bib7","doi-asserted-by":"crossref","first-page":"8308","DOI":"10.1038\/sj.onc.1205091","article-title":"The regulation and function of the Id proteins in lymphocyte development","volume":"20","author":"Rivera","year":"2001","journal-title":"Oncogene"},{"key":"2026011203072886000_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/35105060","article-title":"The function of E- and Id proteins in lymphocyte development","volume":"1","author":"Engel","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"2026011203072886000_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrc3638","article-title":"The ID proteins: master regulators of cancer stem cells and tumour aggressiveness","volume":"14","author":"Lasorella","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2026011203072886000_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"2026011203072886000_bib11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"key":"2026011203072886000_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng1521","article-title":"Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia","volume":"37","author":"Yu","year":"2005","journal-title":"Nat Genet"},{"key":"2026011203072886000_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ccell.2016.05.019","article-title":"Id2 and E Proteins orchestrate the initiation and maintenance of MLL-rearranged acute myeloid leukemia","volume":"30","author":"Ghisi","year":"2016","journal-title":"Cancer Cell"},{"key":"2026011203072886000_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41408-022-00759-6","article-title":"In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors","volume":"12","author":"Aktas Samur","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026011203072886000_bib15","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41375-018-0116-y","article-title":"Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma","volume":"32","author":"Samur","year":"2018","journal-title":"Leukemia"},{"key":"2026011203072886000_bib16","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026011203072886000_bib17","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","article-title":"The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities","volume":"5","author":"Ramberger","year":"2024","journal-title":"Nat Cancer"},{"key":"2026011203072886000_bib18","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1038\/s41467-022-33142-x","article-title":"Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma","volume":"13","author":"Yang","year":"2022","journal-title":"Nat Commun"},{"key":"2026011203072886000_bib19","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1038\/s41388-022-02314-w","article-title":"Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer","volume":"41","author":"R\u00e4tze","year":"2022","journal-title":"Oncogene"},{"key":"2026011203072886000_bib20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1101\/gad.203984.112","article-title":"Tumor suppressor activity of the ERK\/MAPK pathway by promoting selective protein degradation","volume":"27","author":"Desch\u00eanes-Simard","year":"2013","journal-title":"Genes Dev"},{"key":"2026011203072886000_bib21","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1038\/s41467-022-32552-1","article-title":"A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues","volume":"13","author":"Saul","year":"2022","journal-title":"Nat Commun"},{"key":"2026011203072886000_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2026011203072886000_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s43018-023-00550-x","article-title":"Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias","volume":"4","author":"de Matos Simoes","year":"2023","journal-title":"Nat Cancer"},{"key":"2026011203072886000_bib24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41588-018-0044-9","article-title":"Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma","volume":"50","author":"Zeid","year":"2018","journal-title":"Nat Genet"},{"key":"2026011203072886000_bib25","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1128\/MCB.24.10.4241-4254.2004","article-title":"Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein","volume":"24","author":"Kowanetz","year":"2004","journal-title":"Mol Cell Biol"},{"key":"2026011203072886000_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.molimm.2022.05.009","article-title":"Regulation and function of Id2 in plasmacytoid dendritic cells","volume":"148","author":"Babcock","year":"2022","journal-title":"Mol Immunol"},{"key":"2026011203072886000_bib27","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1038\/s41467-024-47793-5","article-title":"Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes","volume":"15","author":"Binder","year":"2024","journal-title":"Nat Commun"},{"key":"2026011203072886000_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ni1285","article-title":"Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma","volume":"7","author":"Mathas","year":"2006","journal-title":"Nat Immunol"},{"key":"2026011203072886000_bib29","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet"},{"key":"2026011203072886000_bib30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood.2021012081","article-title":"SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma","volume":"139","author":"Wilke","year":"2022","journal-title":"Blood"},{"key":"2026011203072886000_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12896-017-0411-0","article-title":"The function of tcf3 in medaka embryos: efficient knockdown with pePNAs","volume":"18","author":"Doenz","year":"2018","journal-title":"BMC Biotechnol"},{"key":"2026011203072886000_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41587-022-01504-x","article-title":"Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains","volume":"41","author":"Speltz","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2026011203072886000_bib33","doi-asserted-by":"crossref","first-page":"e19760","DOI":"10.7554\/eLife.19760","article-title":"Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation","volume":"5","author":"Horlbeck","year":"2016","journal-title":"Elife"},{"key":"2026011203072886000_bib34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol"},{"key":"2026011203072886000_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"key":"2026011203072886000_bib36","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat Methods"},{"key":"2026011203072886000_bib37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.immuni.2019.09.004","article-title":"Transcriptional atlas of intestinal immune cells reveals that neuropeptide alpha-CGRP modulates group 2 innate lymphoid cell responses","volume":"51","author":"Xu","year":"2019","journal-title":"Immunity"},{"key":"2026011203072886000_bib38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat Methods"},{"key":"2026011203072886000_bib39","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/gb-2008-9-9-r137","article-title":"Model-based analysis of ChIP-seq (MACS)","volume":"9","author":"Zhang","year":"2008","journal-title":"Genome Biol"},{"key":"2026011203072886000_bib40","first-page":"D180","article-title":"ReMap 2020: a database of regulatory regions from an integrative analysis of human and arabidopsis DNA-binding sequencing experiments","volume":"48","author":"Ch\u00e8neby","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026011203072886000_bib41","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ccell.2024.05.026","article-title":"IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma","volume":"42","author":"Bolomsky","year":"2024","journal-title":"Cancer Cell"},{"key":"2026011203072886000_bib42","doi-asserted-by":"crossref","first-page":"D316","DOI":"10.1093\/nar\/gkab996","article-title":"ReMap 2022: a database of human, mouse, Drosophila and Arabidopsis regulatory regions from an integrative analysis of DNA-binding sequencing experiments","volume":"50","author":"Hammal","year":"2022","journal-title":"Nucleic Acids Res"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0048\/3660591\/bcd-25-0048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0048\/3716947\/bcd-25-0048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/1\/129\/3723373\/bcd-25-0048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/1\/129\/3723373\/bcd-25-0048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:07:44Z","timestamp":1768205264000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/1\/129\/771360\/ID2-Suppresses-Multiple-Myeloma-Cell-Proliferation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0048","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.31046979","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31046976","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31046973","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31046985","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31046982","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31046970","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8239500","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}